Intended for healthcare professionals

Letters Anti-VEGF treatment

Safety of intravitreal anti-VEGFs during pregnancy is unclear

BMJ 2012; 345 doi: (Published 09 July 2012) Cite this as: BMJ 2012;345:e4526
  1. Ilias Georgalas, consultant vitreoretinal surgeon1,
  2. Petros Petrou, vitreoretinal fellow2,
  3. Chrysanthi Koutsandrea, consultant vitreoretinal surgeon1
  1. 1Department of Ophthalmlogy, University of Athens, 11527 Athens, Greece
  2. 2Birmingham and Midland Eye Centre, Birmingham B18 7QH, UK
  1. igeorgalas{at}

We agree that there are safety issues surrounding the use of anti-vascular endothelial growth factor (VEGF) agents.1

Younger patients may also be treated with intravitreal anti-VEGF and the suppression of plasma VEGF concentrations …

View Full Text

Log in

Log in through your institution


* For online subscription